Boston Scientific has completed its acquisition of Valencia Technologies, adding the innovative eCoin tibial nerve stimulator to its urology portfolio for treating urge urinary incontinence and enhancing its competitive position in the neuromodulation market.
Glimpse:
The deal, originally announced in January 2026, gives Boston Scientific ownership of the eCoin system a coin sized implantable device approved by the FDA in 2022 that stimulates the tibial nerve near the ankle to regulate bladder function. Clinical studies showed that 68% of patients experienced at least a 50% reduction in urge incontinence episodes. This move allows Boston Scientific to offer multiple neuromodulation options alongside its Axonics sacral neuromodulation system, targeting an under penetrated market while competing with players like Medtronic.
Boston Scientific Corporation has successfully closed its acquisition of Valencia Technologies, a California-based medical technology firm specializing in solutions for bladder dysfunction. The transaction, first revealed in January 2026, integrates Valencia’s flagship eCoin system into Boston Scientific’s growing urology and pelvic health offerings. The eCoin device is a small, implantable tibial nerve stimulator placed near the ankle that delivers automatic, intermittent stimulation to help restore proper communication between the brain and bladder, providing relief for people suffering from urge urinary incontinence, a common symptom of overactive bladder.
With this addition, Boston Scientific now offers a broader range of neuromodulation therapies. The company already markets the Axonics sacral neuromodulation system for overactive bladder and fecal incontinence, allowing it to provide physicians and patients with complementary treatment alternatives. The eCoin technology, which received FDA premarket approval in 2022, demonstrated strong results in clinical trials, with 68% of participants achieving at least a 50% decrease in urinary urge incontinence episodes. This minimally invasive option is seen as an attractive choice for patients seeking alternatives to more complex procedures.
The urinary incontinence market remains significantly under penetrated, presenting substantial growth potential. Analysts project sustained double digit compound annual growth for the tibial nerve stimulation segment, driven by improved reimbursement, physician education, and rising patient awareness. Valencia Technologies was expected to generate around $10 million in net revenue for 2025, with a forecasted 20% year-over-year increase. Boston Scientific plans to accelerate adoption of the eCoin system by leveraging its established commercial infrastructure, sales expertise, and relationships in the urology field.
This acquisition marks Boston Scientific’s second deal closure in 2026 and underscores its strategy to expand in high potential areas of neuromodulation and pelvic health. By combining Valencia’s innovative implantable technology with its own portfolio, the company aims to deliver more personalized and effective solutions to a larger number of patients struggling with bladder control issues.
“We’re excited to welcome the Valencia Technologies team to Boston Scientific. Their work is already making a difference for patients, and we look forward to building on that impact together.”
By
HB Team
Related News
